Summary
This 8-K filing from Axon Enterprise, Inc. (formerly TASER International, Inc.) on November 27, 2013, primarily addresses the company's litigation strategy and recent settlement activity. Axon highlights the effectiveness of risk management strategies implemented in 2009, which have significantly reduced product liability cases, leading to expectations of substantial legal expense savings starting in the second half of 2014. The company generally adheres to a policy of not settling injury or death cases unless strategically beneficial, particularly for pre-2009 cases where litigation exposure and the risk of high jury verdicts warrant exceptions.
Key Highlights
- 1Axon has implemented effective risk management strategies since 2009, leading to a significant reduction in active product liability cases from 55 to 22 between Q3 2011 and Q3 2013.
- 2The company experienced zero new lawsuits in the third quarter of 2013, indicating success in mitigating litigation.
- 3Management anticipates significant savings in legal expenses starting in the second half of 2014 due to these strategies.
- 4Axon settled two pre-2009 product liability lawsuits in November 2013 for a combined total of $2.3 million due to litigation exposure exceeding insurance coverage and the risk of adverse jury verdicts.
- 5The expense related to these settlements will be recognized in the fourth quarter of 2013.
- 6Axon reaffirms its policy to aggressively defend litigation and generally not settle, with exceptions only in very limited and unusual circumstances.
- 7The filing includes forward-looking statements regarding litigation strategy, anticipated benefits, and outcomes, subject to various risk factors.
Frequently Asked Questions
The primary purpose of this 8-K filing is to inform investors about Axon's litigation strategy, the success of its risk management initiatives in reducing product liability cases, and details regarding recent settlement activity for older lawsuits.
Axon implemented new risk management strategies, including revised product warnings and training, in 2009. These strategies have been highly effective, leading to a significant decrease in active product liability cases and zero new lawsuits in Q3 2013, with expectations of substantial legal expense savings from the second half of 2014.
Axon settled these two specific pre-2009 cases because they presented a litigation exposure that exceeded insurance coverage and carried a significant risk of potentially high jury verdicts. The settlements were considered strategically beneficial to reduce caseload, legal costs, and overall exposure.
Axon's general policy is not to settle suspect injury or death cases. Exceptions are made only when settlement is strategically beneficial to the company, particularly for older cases with significant exposure and risk of adverse outcomes. The company intends to continue aggressively defending litigation.